TY - JOUR
T1 - Effects of calcium entry blocker (nicardipine) tocolysis rhesus macaques
T2 - Fetal plasma concentrations and cardiorespiratory changes
AU - Ducsay, Charles A.
AU - Thompson, Jeffry S.
AU - Wu, Anne T.
AU - Novy, Miles J.
N1 - Tocolytic doses of nicardipine, a dihydropyridine calcium entry blocker, were administered to chronically catheterized rhesus monkeys between days 128 and 132 of gestation. During periods of spontaneous uterine contractility, a 500 micrograms nicardipine bolus was injected intravenously, and this wa ...
PY - 1987
Y1 - 1987
N2 - Tocolytic doses of nicardipine, a dihydropyridine calcium entry blocker, were administered to chronically catheterized rhesus monkeys between days 128 and 132 of gestation. During periods of spontaneous uterine contractility, a 500 µg nicardipine bolus was injected intravenously, and this was followed by continuous infusion (6 µg/kg/min) to the mother for 1 hour. Uterine activity (amniotic fluid pressure) and maternal heart rate and blood pressure were monitored continuously. Paired maternal and fetal blood samples were drawn at frequent intervals to monitor pH, PCO2, PCO2, and plasma nicardipine concentrations. Peak maternal nicardipine concentrations ranged from 175 to 865 ng/ml while peak fetal levels ranged from 7 to 35 ng/ml. Fetal heart rate and blood pressure were unaffected. However, fetuses became acidotic (pH 7.26 ± 0.01 versus 7.33 ± 0.01) and hypoxemic (PO216.0 ± 3.2 versus 24.5 ± 2.0 mm Hg) after maternal nicardipine treatment (p < 0.01). Despite the fact that maternal nicardipine treatment exerted a significant tocolytic effect, the undesirable fetal side effects are of concern and deserve further investigation.
AB - Tocolytic doses of nicardipine, a dihydropyridine calcium entry blocker, were administered to chronically catheterized rhesus monkeys between days 128 and 132 of gestation. During periods of spontaneous uterine contractility, a 500 µg nicardipine bolus was injected intravenously, and this was followed by continuous infusion (6 µg/kg/min) to the mother for 1 hour. Uterine activity (amniotic fluid pressure) and maternal heart rate and blood pressure were monitored continuously. Paired maternal and fetal blood samples were drawn at frequent intervals to monitor pH, PCO2, PCO2, and plasma nicardipine concentrations. Peak maternal nicardipine concentrations ranged from 175 to 865 ng/ml while peak fetal levels ranged from 7 to 35 ng/ml. Fetal heart rate and blood pressure were unaffected. However, fetuses became acidotic (pH 7.26 ± 0.01 versus 7.33 ± 0.01) and hypoxemic (PO216.0 ± 3.2 versus 24.5 ± 2.0 mm Hg) after maternal nicardipine treatment (p < 0.01). Despite the fact that maternal nicardipine treatment exerted a significant tocolytic effect, the undesirable fetal side effects are of concern and deserve further investigation.
KW - Uterine contractility
KW - fetus
KW - nicardipine
KW - rhesus monkey
UR - https://www.scopus.com/pages/publications/0023573887
UR - https://www.scopus.com/pages/publications/0023573887#tab=citedBy
U2 - 10.1016/S0002-9378(87)80248-X
DO - 10.1016/S0002-9378(87)80248-X
M3 - Article
C2 - 3425651
SN - 0002-9378
VL - 157
SP - 1482
EP - 1486
JO - American Journal of Obstetrics and Gynecology
JF - American Journal of Obstetrics and Gynecology
IS - 6
ER -